BSI-128 / Biosion, Anhui Anke Biotech - LARVOL DELTA

BSI-128 (AK2024) enhances trastuzumab function and potentiates trastuzumab-deruxtecan activity across HER2-positive preclinical models (AACR 2026) - "These data robustly support BSI-128 as a differentiated trastuzumab-synergy antibody with improved performance relative to pertuzumab and the competing synergy antibody when combined with T-Dxd. These findings support the clinical development of BSI-128 plus T-Dxd for HER2-positive gastric cancer and other T-Dxd-approved indications. BSI-128 is currently being evaluated in a Phase 1 clinical trial."

Preclinical • Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2